T0	Interventions 54 65	Ocriplasmin
T1	Interventions 109 158	Microplasmin for Intravitreous Injection-Traction
T2	Interventions 241 269	vitreomacular adhesion (VMA)
T3	Interventions 449 473	intravitreal ocriplasmin
T4	Interventions 581 593	(NEI VFQ-25)
T5	Interventions 1297 1311	of ocriplasmin
T6	Interventions 1321 1358	or placebo-injected vehicle (placebo)
T7	Interventions 1360 1374	The NEI VFQ-25
T8	Interventions 1417 1438	following ocriplasmin
T9	Interventions 1519 1539	follow-up NEI VFQ-25
T10	Interventions 1703 1723	received ocriplasmin
T11	Interventions 1732 1748	received placebo
T12	Interventions 1837 1851	the NEI VFQ-25
T13	Interventions 1873 1884	the placebo
T14	Interventions 2034 2056	for the ocriplasmin vs
T15	Interventions 2262 2279	higher proportion
T16	Interventions 2440 2462	respectively; P = .03)
T17	Interventions 2540 2552	their visual
T18	Interventions 2669 2692	various subscale scores
T19	Interventions 2770 2777	day 28.
T20	Interventions 2778 2789	CONCLUSIONS